Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362489865> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4362489865 abstract "<div>Abstract<p>Tumors can exploit the indoleamine 2,3-dioxygenase 1 (IDO1) pathway to create an immunosuppressive microenvironment. Activated IDO1 metabolizes tryptophan into immunosuppressive kynurenine, leading to suppressed effector T-cell (Teff) proliferation, allowing for tumor escape from host immune surveillance. IDO1 inhibition counteracts this immunosuppressive tumor microenvironment and may improve cancer outcomes, particularly when combined with other immunotherapies. Linrodostat mesylate (linrodostat) is a potent, selective oral IDO1 inhibitor that occupies the heme cofactor–binding site to prevent further IDO1 activation and is currently in multiple clinical trials for treatment of patients with advanced cancers. Here, we assess the <i>in vitro</i> potency, <i>in vivo</i> pharmacodynamic (PD) activity, and preclinical pharmacokinetics (PKs) of linrodostat. Linrodostat exhibited potent cellular activity, suppressing kynurenine production in HEK293 cells overexpressing human IDO1 and HeLa cells stimulated with IFNγ, with no activity against tryptophan 2,3-dioxygenase or murine indoleamine 2,3-dioxygenase 2 detected. Linrodostat restored T-cell proliferation in a mixed-lymphocyte reaction of T cells and allogeneic IDO1-expressing dendritic cells. <i>In vivo</i>, linrodostat reduced kynurenine levels in human tumor xenograft models, exhibiting significant PD activity. Linrodostat demonstrated a PK/PD relationship in the xenograft model, preclinical species, and samples from patients with advanced cancers, with high oral bioavailability in preclinical species and low to moderate systemic clearance. Our data demonstrate that linrodostat potently and specifically inhibits IDO1 to block an immunosuppressive mechanism that could be responsible for tumor escape from host immune surveillance with favorable PK/PD characteristics that support clinical development.</p></div>" @default.
- W4362489865 created "2023-04-05" @default.
- W4362489865 creator A5003341865 @default.
- W4362489865 creator A5009578010 @default.
- W4362489865 creator A5017772706 @default.
- W4362489865 creator A5024322621 @default.
- W4362489865 creator A5060204605 @default.
- W4362489865 creator A5066063320 @default.
- W4362489865 creator A5074508698 @default.
- W4362489865 date "2023-04-03" @default.
- W4362489865 modified "2023-10-03" @default.
- W4362489865 title "Data from Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor" @default.
- W4362489865 doi "https://doi.org/10.1158/1535-7163.c.6542874.v1" @default.
- W4362489865 hasPublicationYear "2023" @default.
- W4362489865 type Work @default.
- W4362489865 citedByCount "0" @default.
- W4362489865 crossrefType "posted-content" @default.
- W4362489865 hasAuthorship W4362489865A5003341865 @default.
- W4362489865 hasAuthorship W4362489865A5009578010 @default.
- W4362489865 hasAuthorship W4362489865A5017772706 @default.
- W4362489865 hasAuthorship W4362489865A5024322621 @default.
- W4362489865 hasAuthorship W4362489865A5060204605 @default.
- W4362489865 hasAuthorship W4362489865A5066063320 @default.
- W4362489865 hasAuthorship W4362489865A5074508698 @default.
- W4362489865 hasBestOaLocation W43624898652 @default.
- W4362489865 hasConcept C150903083 @default.
- W4362489865 hasConcept C185592680 @default.
- W4362489865 hasConcept C202751555 @default.
- W4362489865 hasConcept C203014093 @default.
- W4362489865 hasConcept C207001950 @default.
- W4362489865 hasConcept C2776090121 @default.
- W4362489865 hasConcept C2776107976 @default.
- W4362489865 hasConcept C2776706248 @default.
- W4362489865 hasConcept C2777503454 @default.
- W4362489865 hasConcept C502942594 @default.
- W4362489865 hasConcept C515207424 @default.
- W4362489865 hasConcept C55493867 @default.
- W4362489865 hasConcept C83478079 @default.
- W4362489865 hasConcept C86803240 @default.
- W4362489865 hasConcept C8891405 @default.
- W4362489865 hasConcept C98274493 @default.
- W4362489865 hasConceptScore W4362489865C150903083 @default.
- W4362489865 hasConceptScore W4362489865C185592680 @default.
- W4362489865 hasConceptScore W4362489865C202751555 @default.
- W4362489865 hasConceptScore W4362489865C203014093 @default.
- W4362489865 hasConceptScore W4362489865C207001950 @default.
- W4362489865 hasConceptScore W4362489865C2776090121 @default.
- W4362489865 hasConceptScore W4362489865C2776107976 @default.
- W4362489865 hasConceptScore W4362489865C2776706248 @default.
- W4362489865 hasConceptScore W4362489865C2777503454 @default.
- W4362489865 hasConceptScore W4362489865C502942594 @default.
- W4362489865 hasConceptScore W4362489865C515207424 @default.
- W4362489865 hasConceptScore W4362489865C55493867 @default.
- W4362489865 hasConceptScore W4362489865C83478079 @default.
- W4362489865 hasConceptScore W4362489865C86803240 @default.
- W4362489865 hasConceptScore W4362489865C8891405 @default.
- W4362489865 hasConceptScore W4362489865C98274493 @default.
- W4362489865 hasLocation W43624898651 @default.
- W4362489865 hasLocation W43624898652 @default.
- W4362489865 hasOpenAccess W4362489865 @default.
- W4362489865 hasPrimaryLocation W43624898651 @default.
- W4362489865 hasRelatedWork W1766299275 @default.
- W4362489865 hasRelatedWork W1983855168 @default.
- W4362489865 hasRelatedWork W2077965685 @default.
- W4362489865 hasRelatedWork W2095727888 @default.
- W4362489865 hasRelatedWork W2152857351 @default.
- W4362489865 hasRelatedWork W2277096347 @default.
- W4362489865 hasRelatedWork W3038084605 @default.
- W4362489865 hasRelatedWork W3096668286 @default.
- W4362489865 hasRelatedWork W4281724538 @default.
- W4362489865 hasRelatedWork W4377233726 @default.
- W4362489865 isParatext "false" @default.
- W4362489865 isRetracted "false" @default.
- W4362489865 workType "article" @default.